New Extravascular Defibrillator Offers Pacing 02/03/26
Welcome to Cardiology Today â Recorded February 03, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac implantable electronic devices and quality of life. Key takeaway: New Extravascular Defibrillator Offers Pacing.
Article Links:
Article 1: Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study. (Circulation)
Article 2: Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes. (Journal of cardiac failure)
Article 3: Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. (Heart rhythm)
Article 4: Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach. (Heart rhythm)
Article 5: Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/
đ Featured Articles
Article 1: Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41628259
Summary: Recent randomized trials demonstrated that transcatheter tricuspid valve interventions improve symptoms, function, and quality of life for patients with severe tricuspid regurgitation. These trials showed that the extent of health status improvement correlates directly with the degree of tricuspid regurgitation reduction. This finding establishes a crucial link between procedural success and patient-reported outcomes for this patient population.
Article 2: Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41628682
Summary: Patients with heart failure, particularly those of lower socioeconomic position, exhibit vulnerability to adverse outcomes resulting from care fragmentation. Care coordination effectively mitigates this care fragmentation, improving patient safety and efficacy. This highlights the critical importance of comprehensive clinician networks to enhance patient outcomes during heart failure care transitions.
Article 3: Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41248780
Summary: The AtaCor parasternal extravascular implantable cardioverter-defibrillator system provides defibrillation and antitachycardia pacing therapy from outside the heart. This new modality utilizes an extravascular lead positioned along the left parasternum, designed to overcome limitations of existing implantable cardioverter-defibrillators. The ASCEND E. V. study introduced this novel system for patients with class one or two A indications for implantable cardioverter-defibrillators, focusing on demonstrating the system’s implant success, acute performance, and 30-day safety.
Article 4: Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41205889
Summary: Substrate-based catheter ablation demonstrates effectiveness for scar-related ventricular tachycardia. Cardiac magnetic resonance is a valuable tool for assessing the arrhythmic substrate, thereby guiding ablation strategies. The study found that understanding three-dimensional ventricular substrate depth via cardiac magnetic resonance has prognostic implications for selecting the optimal ventricular tachycardia ablation approach. This approach can inform the decision for endoepicardial access, which may be needed for epicardial ventricular tachycardia despite higher risks.
Article 5: Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41205887
Summary: Lead-related venous stenosis is observed in up to 35 percent of patients with cardiac implantable electronic devices. While most cases are asymptomatic, progressive stenosis causes symptomatic venous obstruction and edema, often proving refractory to anticoagulation therapy. Traditional percutaneous balloon venoplasty offers only transient symptomatic relief due to high recurrence rates when transvenous leads remain implanted. Drug-coated balloon venoplasty addresses these limitations by inhibiting intimal hyperplasia, a mechanism designed to improve long-term patency.
đ Transcript
Today’s date is February 03, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study. Recent randomized trials demonstrated that transcatheter tricuspid valve interventions improve symptoms, function, and quality of life for patients with severe tricuspid regurgitation. These trials showed that the extent of health status improvement correlates directly with the degree of tricuspid regurgitation reduction. This finding establishes a crucial link between procedural success and patient-reported outcomes for this patient population.
Article number two. Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes. Patients with heart failure, particularly those of lower socioeconomic position, exhibit vulnerability to adverse outcomes resulting from care fragmentation. Care coordination effectively mitigates this care fragmentation, improving patient safety and efficacy. This highlights the critical importance of comprehensive clinician networks to enhance patient outcomes during heart failure care transitions.
Article number three. Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. The AtaCor parasternal extravascular implantable cardioverter-defibrillator system provides defibrillation and antitachycardia pacing therapy from outside the heart. This new modality utilizes an extravascular lead positioned along the left parasternum, designed to overcome limitations of existing implantable cardioverter-defibrillators. The ASCEND E. V. study introduced this novel system for patients with class one or two A indications for implantable cardioverter-defibrillators, focusing on demonstrating the system’s implant success, acute performance, and 30-day safety.
Article number four. Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach. Substrate-based catheter ablation demonstrates effectiveness for scar-related ventricular tachycardia. Cardiac magnetic resonance is a valuable tool for assessing the arrhythmic substrate, thereby guiding ablation strategies. The study found that understanding three-dimensional ventricular substrate depth via cardiac magnetic resonance has prognostic implications for selecting the optimal ventricular tachycardia ablation approach. This approach can inform the decision for endoepicardial access, which may be needed for epicardial ventricular tachycardia despite higher risks.
Article number five. Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis. Lead-related venous stenosis is observed in up to 35 percent of patients with cardiac implantable electronic devices. While most cases are asymptomatic, progressive stenosis causes symptomatic venous obstruction and edema, often proving refractory to anticoagulation therapy. Traditional percutaneous balloon venoplasty offers only transient symptomatic relief due to high recurrence rates when transvenous leads remain implanted. Drug-coated balloon venoplasty addresses these limitations by inhibiting intimal hyperplasia, a mechanism designed to improve long-term patency.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
cardiac implantable electronic devices, quality of life, care transitions, tricuspid regurgitation, ventricular tachycardia, cardiac magnetic resonance, intimal hyperplasia, extravascular implantable cardioverter-defibrillator, defibrillation, transcatheter tricuspid valve intervention, arrhythmic substrate, antitachycardia pacing, catheter ablation, parasternal, care fragmentation, extravascular lead, endoepicardial access, patient reported outcomes, drug-coated balloon, care coordination, lead-related venous stenosis, socioeconomic position, venoplasty, Tri-QOL Study, heart failure.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow